BridgeMD
New treatment option for Psychiatric Disorders
Official title Gaze-Contingent Music Therapy Augmentation of CBT for Pediatric Anxiety
ClinicalTrials.gov ID: NCT06595953
What this study is testing
- What it's testing
- Background: Anxiety disorders are becoming more common among children and teenagers. Anxiety can lead to long-term physical and mental problems, such as depression.
- Phase 2: a mid-size study of how well it works
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 8 to 17
You may be able to join if
- In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Ability of subject and parent to understand the study and the willingness to assent/consent into the study.
- Males and females; Age 8-17
- Clinician confirmed diagnosis of ongoing separation anxiety disorder, generalized anxiety disorder, or social anxiety disorder. A clinician will...
- Willingness to adhere to 12 weekly in-person sessions of CBT
You likely can't join if
- An individual who meets any of the following criteria will be excluded from participation in this study:
- Current use of any psychotropic medication
- Ongoing participation in another treatment or intervention study
- Ongoing mental health treatment outside of NIH
- Any mental health diagnosis aside from an anxiety disorder as determined by the Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS)
- Any serious medical conditions
See the full eligibility criteria
- In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Ability of subject and parent to understand the study and the willingness to assent/consent into the study.
- Males and females; Age 8-17
- Clinician confirmed diagnosis of ongoing separation anxiety disorder, generalized anxiety disorder, or social anxiety disorder. A clinician will review a KSADS-PL DSM-5 (November 2016) (Kiddie Schedule for Affective...
- Willingness to adhere to 12 weekly in-person sessions of CBT
- Enrolled in Protocol 01-M-0192
- people must speak, read and write English to be able to participate
- All people will have IQ\>70 as assessed by a WASI or assessment by trained clinical staff which will have occurred under Protocol 01-M-0192
- An individual who meets any of the following criteria will be excluded from participation in this study:
- Current use of any psychotropic medication
- Ongoing participation in another treatment or intervention study
- Ongoing mental health treatment outside of NIH
- Any mental health diagnosis aside from an anxiety disorder as determined by the Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS)
- Any serious medical conditions
- Restrictions that preclude in-person attendance of therapy
The study team makes the final eligibility decision.
Where it's taking place
- Bethesda, Maryland, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 8 years to 17 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Bethesda, Maryland, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.